Exelixis, Inc. - Common Stock (NQ:EXEL)

64.97 -0.14 (-0.22%)

Delayed Quote Updated: 3:01 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

February 25, 2025

From Exelixis, Inc.

Via Business Wire

This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

February 24, 2025

Via Benzinga

Why Exelixis Stock Trounced the Market on Thursday ↗

February 21, 2025

Via The Motley Fool

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? ↗

February 21, 2025

Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.

Via Benzinga

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

February 20, 2025

From Exelixis, Inc.

Via Business Wire

A Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts ↗

February 12, 2025

Via Benzinga

2 Stocks to Buy With Less Than $40 ↗

February 10, 2025

Via The Motley Fool

Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. ↗

February 19, 2025

NASDAQ:EXEL is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

Via Chartmill

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week ↗

February 17, 2025

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

Via Stocktwits

Bullish Setups ↗

February 16, 2025

You know things are bad when I stoop to offering some bullish setups, but that’s just where we’re at right now.

Via Talk Markets

Topics Stocks / Equities

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

February 15, 2025

From Exelixis, Inc.

Via Business Wire

15 Analysts Have This To Say About Exelixis ↗

January 15, 2025

Via Benzinga

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

February 13, 2025

From Exelixis, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 12, 2025

Via Benzinga

Exelixis (EXEL) Q4 2024 Earnings Call Transcript ↗

February 11, 2025

EXEL earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Exelixis Posts 63.7% Profit Surge ↗

February 11, 2025

Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive pressures and regulatory challenges remain.

Via The Motley Fool

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

February 11, 2025

From Exelixis, Inc.

Via Business Wire

Earnings Scheduled For February 11, 2025 ↗

February 11, 2025

Via Benzinga

NASDAQ:EXEL: good value for what you're paying. ↗

February 04, 2025

EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

January 28, 2025

From Exelixis, Inc.

Via Business Wire

Investors should take note of NASDAQ:EXEL, a growth stock that remains attractively priced. ↗

January 27, 2025

Uncover the potential of EXELIXIS INC, a growth stock reasonably priced. NASDAQ:EXEL is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation.

Via Chartmill

Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday ↗

January 27, 2025

Via Benzinga

This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

January 27, 2025

Via Benzinga

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

January 25, 2025

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

January 24, 2025

From Exelixis, Inc.

Via Business Wire

BeiGene Stock Meets 80-Plus RS Rating Benchmark ↗

January 15, 2025

One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.

Via Investor's Business Daily

BridgeBio Pharma Stock Earns 87 RS Rating ↗

January 14, 2025

BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.

Via Investor's Business Daily

NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals. ↗

January 14, 2025

EXELIXIS INC (NASDAQ:EXEL) is probably undervalued for the fundamentals it is displaying.

Via Chartmill

SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 ↗

January 13, 2025

On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.

Via Investor's Business Daily

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

January 12, 2025

From Exelixis, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.